rs5443

 

Chromosome 12
Position 6845711
Gene HTR2A

CT

41.343%

CC (GG)

30.231.4%

TT (AA)

24.625.6%

Breakdown:

rs5443 is a SNP in the HTR2A (GNB3) gene. It is associated with a number of metabolic conditions like obesity, diabetes, coronary heart diseases etc.

  • This SNP codes for GNB3, which in turn codes for a second messenger complex associated with 5HT2A receptor signaling (Ref).

The T (A) allele is associated with:

  • Better response to viagra, more likely to be obese, hypertension, SSRI-induced sexual dysfunction, respond to triptans for migraines (TT or AA). T (A) allele carriers are 2-3 fold more likely to be obese in Caucasian, Chinese, and African American populations (Ref).
  • Higher risk for hypertension (Ref).
  • Significant weight gain during pregnancy (TT [AA] vs CT [GA] or CC [GG]).  Women had a significantly higher pre-pregnancy body mass index (Ref).
  • Better response to Viagra (TT or AA). 91% of them have a “positive erectile response” upon taking Viagra, whereas only around 50% of CT (GA) and CC (GG) individuals respond equivalently to the drug (OR=10, p = 0.01) (R).
  • Significant weight gain while taking anti-depressants.  Patients with TT (AA) receiving clozapine over a long term for the treatment of schizophrenia gain significantly more weight (16%) compared to patients carrying at least one C allele in a study of Chinese patients (Ref).
  • Better response to Triptans.  T (A) carriers taking triptans for the treatment of migraines or cluster headaches were ~3 fold more likely to respond positively compared with CC (OR 2.96, p=0.0074) in a study of ~200 Caucasian patients (Ref).
  • The T (A) allele is thought to increase secondary messenger signalling (Ref).

The C (G) allele is associated with:

  • GERD. CT (GA) genotypes are more prevalent in gastroesophageal reflux disease (GERD) patients relative to healthy controls (OR 1.43) (Ref).
  • An inability to lose weight with the drug sibutramine. CC (GG) individuals do not lose weight under sibutramine (weight loss drug) therapy whereas CT (GA) and TT (AA) individuals do according to a study of 131 obese Taiwanese patients (Ref).

Research articles:

[PMID 21371559] Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers-a SPECT study

[PMID 21675276] [A protective effect of GLY272SER polymorphism of GNB3 gene in development of essential hypertension and its relations with environmental hypertension risk factors] [PMID 22041889] Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitor treatment: Are g-protein (beta)3 subunit genotype, helicobacter pylori status, and environmental factors response modifiers?

[PMID 22791279] Association of the C825T polymorphism in the GNB3 gene with obesity and metabolic phenotypes in a Taiwanese population

[PMID 17521439] Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach.

[PMID 18248681] Prevalence of common disease-associated variants in Asian Indians.

[PMID 18304332] No evidence for association between BMI and 10 candidate genes at ages 4, 7 and 10 in a large UK sample of twins.

[PMID 18308786] The –1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.

[PMID 18513389] New application of intelligent agents in sporadic amyotrophic lateral sclerosis identifies unexpected specific genetic background.

[PMID 18656447] Salt consumption-dependent association of the GNB3 gene polymorphism with type 2 DM.

[PMID 19131662] A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients.

[PMID 19263529] Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach.

[PMID 19303909] Intensity of opiate withdrawal in relation to the 825C>T polymorphism of the G-protein beta 3 subunit gene.

[PMID 19330901] Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women’s Genome Health Study.

[PMID 19360113] The Role of the PGC1alpha Gly482Ser Polymorphism in Weight Gain due to Intensive Diabetes Therapy.

[PMID 19559392] A candidate gene association study of 77 polymorphisms in migraine.

[PMID 19885780] GNB3 C825T polymorphism and elevated blood pressure.

[PMID 20021678] Evaluation of self-reported ethnicity in a case-control population: the stroke prevention in young women study.

[PMID 20359253] Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population.

[PMID 20386734] Further evidence supporting a role for gs signal transduction in severe malaria pathogenesis.

[PMID 21172166] Pharmacogenetics of antidepressant response.

[PMID 21210858] Is there an interaction between BDKRB2 -9/+9 and GNB3 C825T polymorphisms and elite athletic performance?

[PMID 21735268] [Genotype of the GNB3 C825T polymorphism, A risk factor for the development and course of prostate cancer?].

[PMID 21737952] Genetic variation in gsalpha protein as a new indicator in screening test for vasovagal syncope.

[PMID 22534794] A two-stage matched case-control study on multiple hypertensive candidate genes in Han Chinese.

[PMID 23339167] Single nucleotide polymorphisms in G protein signaling pathway genes in preeclampsia.

[PMID 23733030] Pharmacogenetics in major depression: a comprehensive meta-analysis.

[PMID 26083990] Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects

[PMID 27660894] Association of CLOCK, ARNTL, PER2, and GNB3 polymorphisms with diurnal preference in a Korean population.

 

EXPRESSION CONTROL

Clinical Tips

 

Activation of 5HT2A receptors is on the whole bad.  The more receptors we have, the more likely they’ll activate, so it’s better to have fewer receptors. 5HT2A receptors are commonly found in platelets, the heart, joints, immune cells (monocytes), the vagus nerve (R) and brain (hypothalamus, brain stem, prefrontal) (R).

Activation of 5HT2A receptors can contribute to many problems, including anxiety, depression, fatigue, OCD, sleep problems, etc. However, some good effects include lowered heart rate and blood pressure and reduced inflammatory effects.

Negative effects:

Activation of 5HT2A receptors contributes to:

  • Anxiety and neuroticism.  In particular, it increases glutamate release and neuronal excitation (R).
  • Increased TGF-beta (R) – this effect is reversed by NAC and lipoic acid (R).
  • Decreased glutathione (R)
  • Reduced BDNF. When activated, these receptors decrease BDNF production (R).  This is the mechanism by which psychological stress reduces BDNF(R).
  • Increased arachidonic acid, which can be inflammatory (R).
  • Suicide and depression. Suicidal and otherwise depressed patients have had more 5-HT2A receptors than normal patients (R). Blocking these receptors is a mechanism of antipsychotics and can help depression (R). This receptor may to some extent account for the difference in the outcome of anti-depressant/SSRI treatment (minor alleles generally more likely to benefit) (R). 5HT2A receptors are in high concentration in the default mode network [DMN], which is overactive in depression (R).  This brain network is implicated in self-related thinking and mind wandering.
  • Chronic Fatigue Syndrome. One study has linked abnormal 5-HT2A polymorphisms which may enhance receptor activity with Chronic Fatigue Syndrome (R).  It’s possible that by activating the 5HT2A receptors, fatigue occurs because orexin neurons are shut off.  Antipsychotics that block 5HT2A receptors were found to activate orexin neurons (R).
  • Insomnia and sleep problems (R).
  • IBS. People with genes who produced more 5HT2A receptors were more likely to have IBS (T allele for ) (R).  When I took LSD (strong 5HT2A activator), it caused serious GI issues, which fits with this.
  • Decreases Slow Wave Sleep (along with 5HT6….. 5-HT1A, 5-HT1B, and 5-HT7 MAOA and serotonin transporters have been implicated in the control of REM sleep) (R).
  • OCD. Higher numbers of 5HT2A receptors in the caudate nuclei are associated with OCD (R). Blocking the 5-HT2 receptor has been shown to enhance therapeutic responses to SSRIs in patients with major depression and treatment-refractory obsessive“compulsive disorder (OCD) (R).
  • Pain. These receptors are found in the spinal cord regions that control pain (R). Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators (R).
  • Autism. These blockers may also be effective in ameliorating some symptoms associated with autism and other pervasive developmental disorders (R).  Autistic people have more 5HT2A receptors (in platelets) (R).
  • Tourette’s (R) and head twitch response (R).
  • Increased prolactin, cortisol and renin (activation of the 5-HT2A in the hypothalamus) (R).
  • Decreased blood flow to the heart (R), skin (R) and other places.  5HT2A causes your blood vessels to narrow (vasoconstriction of smooth muscle cells) (R). Decreased blood flow can contribute to people feeling colder.
  • Increased platelet clumping (R), which can worsen blood flow and cause heart disease.

Benefits

Activators of 5HT2A (R):

  • Lower heart rate and lower blood pressure (mediated by the vagus nerve) (R, R2).
  • Reduce inflammatory effects in several tissues including the heart and gut (especially against TNF-induced inflammation).
  • Enhance dopamine in the areas responsible for a higher level of thinking (PFC), which enhances memory and plays a role in attention and learning.
  • Reduce pressure in the eye,
  • Increase oxytocin and ACTH (activation of the 5-HT2A in the hypothalamus).

The lower heart rate and blood pressure are produced via the inhibition of Rostral Ventrolateral Medulla (RVLM) in the brainstem, which controls the baroreflex (R).

The baroreflex controls blood pressure and people with chronic fatigue often have low blood pressure.  These effects could, in part, be mediated by the 5HT2A receptors. Other effects could be as a result of lower orexin activation, as orexin neurons from the hypothalamus stimulate the RVLM (R).

The RVLM is the primary regulator of the fight or flight nervous system, sending excitatory signals to the sympathetic preganglionic neurons in the spinal cord, via reticulospinal tract (R).

In animals, the 5-HT2A receptors increase body heat by causing vasoconstriction in skin (mediated by brainstem) (R).

A haplotype consisting of 4 SNPs in the HTR2A gene has been associated with risk for rheumatoid arthritis [PMID 18006541]; the 4 SNPs being:

  • rs6311
  • rs6313
  • rs1328674
  • rs6314

A SNP in the HTR2A gene, rs7997012 and another gene (GRIK4) may also influence the odds of success upon treatment with the antidepressant citalopram, potentially differently in patients of different ethnic backgrounds.[PMID 17671280]

Activation of 5HT2A receptors can contribute to many problems, including anxiety, depression, fatigue, OCD, sleep problems, etc. However, some good effects include lowered heart rate and blood pressure and reduced inflammatory effects.

  • Inositol – reduces 5HT2A receptor function (R),
  • Meditation,
  • Zinc (R),
  • Feverfew (R)
  • Ginkgo (R)

Inositol and fluoxetine reduce 5HT2A receptor function at the receptor-G protein level.  In addition mI, and at high concentrations fluoxetine and imipramine, also reduces muscarinic acetylcholine receptors (R).

5HT2A receptors are in high concentration in the default mode network [DMN], which is overactive in depression (R).  

This brain network is implicated in self-related thinking and mind wandering. Meditation leads to a reduced activity in the default mode network (R), which can help some of the negative effects of the 5HT2A receptors on depression.

The negative effects of the 5HT2A receptors seem to work through activating GSK3 (R) and stimulating calcium release inside cells. Therefore, GSK3 inhibitors such as lithium might help.  

Magnesium can help with calcium release. 5-HT2A has sialic acid in it, which is bound to by lectins.  Lectins probably modify the receptor in some negative way in people who are susceptible.

  • SSRIs,
  • Sialic Acid?
  • MDMA (R) -in recent MDMA users, post-synaptic 5-HT(2A) receptor densities were significantly lower in all cortical areas studied,

Lithium inhibits GSK3b (R), which can help regulate this gene, but it also decreases brain inositol (R). Some studies show St Johns Wort decreases 5HT2A receptors (R).

Other studies report a 50-percent increase in 5-HT2A receptors after six months of use of St. Johns Wort so it looks like to benefit is limited in time.(R).  

 

Decrease activity ↓
  • Olanzapine (R)
  • Sarpogrelate (R R)
  • Aripiprazole (R)
  • N,N-Dimethyltryptamine (R)
  • Paliperidone Palmitate (R)
  • Ritanserin (R)
  • Tryptamine (R)
  • Ziprasidone (R)
  • Cyproheptadine (R)
  • Spiperone (R)
  • Norclozapine (R)
  • Lithium Chloride
  • (+)-JQ1 compound (R)
  • Perphenazine GABA ester (R)
  • Quetiapine Fumarate (R)

 

Increase activity
  • Risperidone (R)
  • Progesterone (R)
  • Palmitic Acid (R)

Non human studies:

  • Dopamine (R) ,(R), (R)
  • Calcium (R) , (R) , (R)
  • Cypermethrin (R) , (R)
  • Estradiol 3-benzoate (R)
  • Chlorpyrifos (R)
  • Zalcitabine (R)
  • Diazinon (R)
  • Freund’s Adjuvant (R)
  • Nanotubes, Carbon (R)
  • Nitrofen (R)
  • Ozone (R)
  • Nicotine (R)
  • Dietary Fats (R)
  • Yohimbine (R)
  • Dexamethasone (R)
  • PCB 180 (R)
  • Propylthiouracil (R)

 

Can work both ways

Non human studies:

  • Ketanserin (R)
  • Corticosterone  (R)
  • Tramadol  (R)
  • Phencyclidine  (R)
  • Tobacco Smoke Pollution (R)
  • Pertussis Toxin (R)
  • Iodopravadoline (R)
  • Colforsin  (R)
  • Streptozocin  (R)